Global evolution of inflammatory bowel disease across epidemiologic stages

The global evolution of inflammatory bowel disease (IBD) can be understood through its progression across four distinct epidemiologic stages, which reflect the changing patterns of incidence, prevalence, and disease burden over time. This evolution is shaped by global socioeconomic, environmental, and healthcare changes, as well as advancements in medical diagnostics and treatment. Below is a detailed explanation of how IBD has evolved across these stages:

### **1. Global Shift of IBD**

• Historically, IBD was concentrated in early industrialized regions such as North America, Europe, and Oceania. However, over the past few decades, it has transitioned into a global disease, increasingly affecting newly industrialized and emerging regions, such as parts of Asia, Latin America, and the Middle East.
• This shift is driven by global socioeconomic and environmental transformations, including industrialization, urbanization, and changes in diet and lifestyle.

---

### **2. The Four Epidemiologic Stages of IBD**

The progression of IBD follows four epidemiologic stages, each defined by specific patterns of incidence and prevalence:

#### **Stage 1: Emergence**

• **Characteristics**: Very low incidence and prevalence of IBD.
• **Regions**: Typically observed in low-income or emerging regions with limited healthcare infrastructure and diagnostic capacity.
• **Challenges**: Sparse epidemiologic data due to underreporting and lack of surveillance.
• **Example**: Many regions in Africa remain in this stage, where the true burden of IBD is likely underestimated.

#### **Stage 2: Acceleration**

• **Characteristics**: Rapidly increasing incidence of IBD, while prevalence remains relatively low.
• **Drivers**: This stage reflects both a true increase in disease occurrence and improved detection due to better healthcare infrastructure, including access to colonoscopy and specialist care.
• **Regions**: Newly industrialized regions, such as parts of Asia, Latin America, and the Middle East, are currently in this stage.
• **Environmental Factors**: Industrialization, urbanization, and westernization-related factors, such as dietary changes, obesity, and altered hygiene practices, are strongly associated with the sharp rise in incidence.

#### **Stage 3: Compounding Prevalence**

• **Characteristics**: Incidence stabilizes or slows, but prevalence rises steadily as more individuals live longer with IBD due to the chronic nature of the disease and low mortality rates.
• **Regions**: Early industrialized regions, including North America, Europe, and Oceania, largely transitioned to this stage by the late 20th century.
• **Challenges**: Healthcare systems in these regions face sustained pressure due to the growing number of people living with IBD, particularly as the population ages and comorbidities increase.
• **Projections**: Mathematical modeling suggests that prevalence will continue to grow in these regions, with a gradual slowing as populations age and incidence stabilizes.

#### **Stage 4: Prevalence Equilibrium (Proposed)**

• **Characteristics**: Prevalence plateaus as mortality approximates incidence. This stage is driven by an ageing IBD population and the stabilization of new cases.
• **Current Status**: Few regions have reached this stage, as it requires decades of data and trends to emerge.
• **Potential Impact**: Modest reductions in incidence through prevention strategies could help accelerate the transition toward this stage in high-burden regions.

---

### **3. Factors Influencing the Evolution of IBD**

Several factors contribute to the global evolution of IBD and the transition between epidemiologic stages:

#### **Environmental and Socioeconomic Drivers**

• Westernization-related factors, such as changes in diet, urban living, obesity, and hygiene practices, are strongly associated with the transition from low to high IBD incidence stages.
• Industrialization and urbanization play a critical role in increasing disease incidence in newly industrialized regions.

#### **Healthcare Infrastructure**

• Improved access to diagnostic tools, such as colonoscopy and specialist care, contributes to the “unmasking” of IBD, particularly during the transition from stage 1 to stage 2.
• Regions with advanced healthcare systems have better capacity to manage the growing prevalence of IBD, but they also face challenges in addressing the long-term care needs of an ageing IBD population.

#### **Changing Disease Patterns**

• The ratio of ulcerative colitis (UC) to Crohn’s disease (CD) decreases across stages, reflecting improved recognition and diagnosis of CD as healthcare infrastructure and diagnostic capacity improve.

---

### **4. Challenges and Burden in Stage 3 Regions**

• **Prevalence Growth**: Stage 3 regions are experiencing rapidly increasing numbers of people living with IBD, placing significant pressure on healthcare systems.
• **Ageing Population**: The accumulation of prevalence over decades has led to a higher proportion of older adults with IBD, complicating disease management due to comorbidities and increased treatment risks.

---

### **5. Future Projections and Policy Implications**

• **Mathematical Modelling**: Partial differential equation models predict continued prevalence growth in stage 3 regions, with a gradual slowing as populations age and incidence stabilizes.
• **Incidence Reduction**: Even modest reductions in incidence through prevention strategies could accelerate the transition toward prevalence equilibrium in high-burden regions.
• **Policy and Planning**: Understanding the stage-specific evolution of IBD enables governments and healthcare systems to anticipate future disease burden, allocate resources efficiently, and prioritize prevention and surveillance strategies.

---

### **6. Summary of Global Trends**

• Early industrialized regions (e.g., North America, Europe, Oceania) have largely transitioned to stage 3, with stabilized incidence but rapidly growing prevalence.
• Newly industrialized regions (e.g., Asia, Latin America, the Middle East) are in stage 2, experiencing sharp increases in incidence due to industrialization and urbanization.
• Emerging regions (e.g., parts of Africa) remain in stage 1, with limited data and diagnostic capacity likely underestimating the true burden of IBD.

---

### **Conclusion**

The global evolution of IBD across epidemiologic stages reflects the interplay between environmental, socioeconomic, and healthcare factors. While early industrialized regions are grappling with the challenges of compounding prevalence and ageing populations, newly industrialized and emerging regions are experiencing rapid increases in incidence. Understanding these stage-specific trends is crucial for policymakers and healthcare systems to effectively manage the growing burden of IBD and prioritize prevention, surveillance, and resource allocation strategies.